When establishing or updating a cell line development (CLD) lab, we all look to minimize short terms effects on productivity and to reap new efficiencies as soon as possible. Physical installation time, establishing new workflow validation and even optimizing media and supplements are all factors that can influence the efficiency and economic viability of introducing …
We are delighted to announce that Solentim will be taking part in the Bioprocess International US West 2021 digital event, taking place 29-31 March. Staying fully committed and connected to our local and international customers, we will be giving a presentation and a holding a Live Labs session during the conference. DAY ONE, Monday, March …
Following Solentim’s new ICON instrument winning the SLAS 2021 New Product Award, Duncan Borthwick, Global Marketing Manager, was invited to discuss Solentim’s innovative products, mission and vision on the New Matter Podcast. Duncan discusses how the company is dedicated to listening to scientists to make better tools to improve cell line development, and shares how …
Read more Solentim features on podcast “New Matter: Inside the Minds of SLAS Scientists”
Bournemouth, UK, 23rd February 2021 / Solentim, the trusted global leader in cell therapy workflows enabling the creation, isolation and characterization of high value cells, announces the opening of a new office in Shanghai. Solentim China is a joint venture with its longstanding distribution partner Trio Biotech Co, and will enhance support for customers and expand …
Read more Solentim expands global reach, opening new operation in China
Bournemouth, UK, 29th January 2021 / Solentim is delighted to have won a New Product Award from the Society for Laboratory Automation and Screening (SLAS), announced this week at SLAS Digital 2021. Solentim achieved this award with the launch of its new ICON™ and STUDIUS™ technologies. ICON is the world’s first benchtop system for characterizing high …
Following the launch of Solentim’s new ICON™ instrument and dedicated STUDIUS™ software, the two of which complete the company’s cutting-edge ecosystem, we spoke with Dr Ian Taylor, Chief Business Officer, Solentim, to find out what this means for cell line development and the future of antibody therapeutics.
